CTLA4 and metastatic melanoma: The CII monoclonal antibodies approved to treat metastatic melanoma patients include ipilimumab (targeting cytotoxic T lymphocyte-associated antigen 4, CTLA-4) [2], nivolumab and pembrolizumab (targeting programmed cell death protein-1, PD-1) [3].